Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review

Basit Öğe Kaydı
dc.authorid-en_US
dc.authorscopusid58095972100en_US
dc.authorwosid-en_US
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorBayrak, Meltem
dc.contributor.authorEskazan, Ahmet Emre
dc.date.accessioned2024-01-23T05:58:48Z
dc.date.available2024-01-23T05:58:48Z
dc.date.issued2023en_US
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractIntroduction: Thromboembolic events in myeloproliferative neoplasms (MPNs) are one of the most important causes of mortality and morbidity, in which vitamin K antagonists (VKAs) have been used mostly. Recently, direct oral anticoagulants (DOACs) are used in venous thromboembolism (VTE) and cancer-associated thrombosis (CAT). With the adoption of data from CAT and VTE, the usage of DOACs in MPNs is increasing. Areas covered: In this paper, we performed a systematic review to the current literature regarding the usage of DOACs in MPNs. Eleven studies involving 944 patients were included. The reasons for initiating DOACs were secondary prophylaxis for thrombosis (arterial or venous) and atrial fibrillation (AF) in 562 and 382 patients, respectively. A total of 84 (8.9%) recurrent thrombotic (arterial or venous) events recorded. Forty-six (8.1%) events occurred in the thrombosis group (arterial or venous) and 38 (9.9%) events occurred in patients with AF. Expert opinion: Ease of management and patient comfort should be regarded as benefits of DOACs compared to VKAs. However, it would be appropriate to bring an individualized approach until we obtain high-quality data with prospectively designed studies involving more patients and longer follow-up time concerning the use of DOACs in patients with MPNs.en_US
dc.identifier.citationBaysal, M., Bayrak, M., & Eşkazan, A. E. (2023). Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Expert Review of Hematology, 16(2), 131–140. https://doi.org/10.1080/17474086.2023.2174515en_US
dc.identifier.doi10.1080/17474086.2023.2174515
dc.identifier.endpage140en_US
dc.identifier.issue2en_US
dc.identifier.pmid36709432
dc.identifier.scopus2-s2.0-85147701783
dc.identifier.startpage131en_US
dc.identifier.urihttps://doi.org/10.1080/17474086.2023.2174515
dc.identifier.uri1747-4086 / 1747-4094
dc.identifier.urihttps://hdl.handle.net/20.500.12428/5314
dc.identifier.volume16en_US
dc.identifier.wosWOS:000934169600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBayrak, Meltem
dc.language.isoen
dc.publisherTaylor and Francis Ltd.en_US
dc.relation.ispartofExpert Review of Hematologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnticoagulation therapyen_US
dc.subjectBleedingen_US
dc.subjectDirect oral anticoagulantsen_US
dc.subjectMPNen_US
dc.subjectMyeloproliferative neoplasmen_US
dc.subjectThrombosisen_US
dc.titleCurrent evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Meltem_Bayrak_Review.pdf
Boyut:
186.47 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Review
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu